Hydnocarpin

Hydnocarpin is a flavonoid compound that demonstrates potent anti-cancer properties through ROS-mediated apoptosis induction in tumor cells. This bioactive compound exhibits dual mechanisms by triggering cancer cell death while simultaneously modulating immune responses against malignant tissues.

Origin & History

Hydnocarpin is a flavonolignan compound extracted from the seeds of Hydnocarpus wightiana, a plant native to South Asia. It is produced through the isolation of the seeds of this plant, containing both flavonoid and lignan structural elements.

Historical & Cultural Context

The traditional or historical use of Hydnocarpus wightiana is not documented in the available literature. There is no information about its applications in Ayurvedic or other traditional medicine systems.

Health Benefits

• Exhibits dual anti-tumor effects on ovarian cancer cells by inducing ROS-mediated apoptosis and modulating immune responses. [1]
• Suppresses T-cell acute lymphoblastic leukemia proliferation via cell cycle arrest and apoptosis. [2]
• Demonstrates good anti-inflammatory and antineoplastic activity in early mouse studies. [6]
• Promotes T-cell activation and reduces immune evasion markers in cancer cells. [1]
• Triggers ferroptosis in cancer cells, enhancing iron-dependent cell death. [2]

How It Works

Hydnocarpin exerts its anti-tumor effects primarily through the generation of reactive oxygen species (ROS), which triggers mitochondrial-mediated apoptosis pathways in cancer cells. The compound induces cell cycle arrest at specific checkpoints, preventing tumor cell proliferation. Additionally, hydnocarpin modulates immune cell function, enhancing the body's natural anti-tumor immune responses through T-cell regulation.

Scientific Research

There are no human clinical trials of hydnocarpin published in peer-reviewed literature. Existing evidence consists of in vitro and limited in vivo studies, such as those on ovarian cancer and T-ALL cell lines. Further in vivo validation is required before clinical translation. [1]

Clinical Summary

Research on hydnocarpin is primarily limited to in vitro and preclinical studies examining its effects on various cancer cell lines. Studies have demonstrated significant anti-proliferative activity against ovarian cancer cells and T-cell acute lymphoblastic leukemia through apoptosis induction and cell cycle arrest. Laboratory investigations have also confirmed anti-inflammatory properties, though specific dosage ranges and bioavailability data remain limited. Human clinical trials are needed to establish therapeutic efficacy and optimal dosing protocols.

Nutritional Profile

Hydnocarpin is a flavonolignan compound (molecular formula C₂₅H₂₂O₁₀, MW ~490 Da) isolated primarily from Hydnocarpus wightiana and members of the Flacourtiaceae family, as well as from milk thistle (Silybum marianum) alongside silybin and silymarin. It is not a dietary macronutrient or micronutrient in the conventional sense; it contains no caloric value, protein, fat, or fiber. As a bioactive flavonolignan, its pharmacological activity is concentration-dependent, with in vitro studies typically employing concentrations in the range of 10–100 µM. Bioavailability is limited due to its polyphenolic structure, which results in low aqueous solubility and susceptibility to hepatic first-pass metabolism — characteristics common to flavonolignans. Like silybin, it likely undergoes glucuronidation and sulfation in the gut and liver. No established dietary reference intake or tolerable upper limit exists. Its primary relevance is as a phytochemical bioactive rather than a nutritional compound.

Preparation & Dosage

Laboratory studies used concentrations of 7.5–15 µM hydnocarpin D for T-ALL cells and animal studies reported no adverse effects at doses up to 5000 mg/kg. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Hydnocarpin pairs well with Silybin (from Silybum marianum), as both are flavonolignans sharing complementary ROS-modulating and apoptosis-inducing pathways, potentially producing additive effects on cancer cell oxidative stress while silybin's better-characterized pharmacokinetics may inform co-formulation strategies. Quercetin is a strong complementary partner because its inhibition of P-glycoprotein (P-gp) efflux transporters can counteract multidrug resistance mechanisms — notably, hydnocarpin itself has been identified as a P-gp substrate and inhibitor, and quercetin's parallel P-gp modulation may amplify intracellular retention of both compounds. Piperine (from Piper nigrum, typically at 5–20 mg alongside flavonoid compounds) enhances the bioavailability of poorly soluble polyphenols by inhibiting glucuronidation enzymes (UGT1A) and P-gp, directly addressing hydnocarpin's bioavailability limitations. Additionally, EGCG (epigallocatechin gallate from green tea) complements hydnocarpin's immune-modulatory anti-tumor effects via independent inhibition of NF-κB and STAT3 signaling pathways, creating a multi-target approach to tumor immune evasion suppression.

Safety & Interactions

Safety data for hydnocarpin in humans is currently limited due to the lack of clinical trials. As a flavonoid compound, it may interact with medications metabolized by cytochrome P450 enzymes, potentially affecting drug clearance. Individuals taking anticoagulant medications should exercise caution, as flavonoids can influence blood clotting mechanisms. Pregnant and breastfeeding women should avoid hydnocarpin supplementation due to insufficient safety data in these populations.